Glossary Term
Mismatch Repair
PCR TermsEN
Definition
The mismatch repair (MMR) system promotes genomic fidelity by repairing base-base mismatches, insertion-deletion loops and heterologies generated during DNA replication and recombination. This function is critically dependent on the assembly of multimeric complexes involved in mismatch recognition and signal transduction to downstream repair events.
Extended Notes
Source: National Cancer Institute, NCI Thesaurus 26.09d, C20639. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-20. No individual clinical interpretation or human reviewer is asserted.
Also Known As
Mismatch RepairMMRPost-Replication Mismatch Repair
References
- NCI Thesaurus 26.09d — Mismatch Repair (C20639)
- Source: National Cancer Institute, NCI Thesaurus 26.09d, C20639. NCI definition, reproduced without modification under CC BY 4.0.
- The evolution of immunotherapy resistance in mismatch repair-deficient colorectal cancer: A spatiotemporal perspective. — Crit Rev Oncol Hematol, 2026-10-20 (PMID 42901333; literature)
- Distinct genomic landscapes of mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancer depending on tumor mutation burden (TMB) levels. — J Immunother Cancer, 2026-10-15 (PMID 42880820; literature)
- Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial. — Lancet, 2026-10-21 (PMID 42906564; literature)
- Redefining curative treatment for early-stage mismatch repair-deficient colon cancer. — Lancet, 2026-10-21 (PMID 42906563; literature)
- Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW. — Ann Oncol, 2026-10-24 (PMID 42926106; literature)
- Extracellular matrix collagen remodeling predicts resistance to immune checkpoint blockade in mismatch repair-deficient endometrial cancer. — J Immunother Cancer, 2026-10-22 (PMID 42914563; literature)
- First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial. — Lancet, 2026-10-26 (PMID 42933458; literature)
- Effect of implementation of a clinical checklist on the evaluation of constitutional mismatch repair deficiency in a neurofibromatosis clinic. — J Community Genet, 2026-10-30 (PMID 42957923; literature)
- Letter re: ELECLA trial: final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer. — ESMO Open, 2026-10-29 (PMID 42956691; literature)